Cargando…

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry

AIMS: Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. METHODS AND RESULTS: We investigated the re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnabel, Renate B, Ameri, Pietro, Siller-Matula, Jolanta M, Diemberger, Igor, Gwechenberger, Marianne, Pecen, Ladislav, Manu, Marius Constantin, Souza, José, De Caterina, Raffaele, Kirchhof, Paulus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540669/ https://www.ncbi.nlm.nih.gov/pubmed/37713182 http://dx.doi.org/10.1093/europace/euad280

Ejemplares similares

Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis( )
por: Diemberger, Igor, et al.
Publicado: (2022)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
por: Patti, Giuseppe, et al.
Publicado: (2017)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
por: de Groot, Joris R, et al.
Publicado: (2020)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries
por: Russo, Vincenzo, et al.
Publicado: (2022)

Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe
por: Schnabel, Renate B., et al.
Publicado: (2018)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation
por: Schnabel, Renate B, et al.
Publicado: (2017)

Can we improve outcomes in AF patients by early therapy?
por: Kirchhof, Paulus
Publicado: (2009)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis
por: Jorda, Anselm, et al.
Publicado: (2021)

Integrated care in stroke survivors: When and how much?
por: Schnabel, Renate B., et al.
Publicado: (2020)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
por: Yamashita, Takeshi, et al.
Publicado: (2018)

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
por: Yamashita, Takeshi, et al.
Publicado: (2020)

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis
por: Grajek, Stefan, et al.
Publicado: (2021)

Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
por: Nagashima, Koichi, et al.
Publicado: (2020)

Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients
por: Choi, Eue‐Keun, et al.
Publicado: (2023)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Gravitational collapse of Mount Etna’s southeastern flank
por: Urlaub, Morelia, et al.
Publicado: (2018)

Long range infrasound monitoring of Etna volcano
por: Marchetti, E., et al.
Publicado: (2019)

AF in Cancer Patients: A Different Need for Anticoagulation?
por: Sanz, Ana Pardo, et al.
Publicado: (2019)

Seismic footprints of shallow dyke propagation at Etna, Italy
por: Falsaperla, Susanna, et al.
Publicado: (2015)

Muographic monitoring of the volcano-tectonic evolution of Mount Etna
por: Lo Presti, D., et al.
Publicado: (2020)

Genetics of atrial fibrillation—practical applications for clinical management: if not now, when and how?
por: Kany, Shinwan, et al.
Publicado: (2021)

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation
por: Siller-Matula, Jolanta M., et al.
Publicado: (2020)

Rapid Speciation with Gene Flow Following the Formation of Mt. Etna
por: Osborne, Owen G., et al.
Publicado: (2013)

First Insights into the Bacterial Diversity of Mount Etna Volcanic Caves
por: Nicolosi, Giuseppe, et al.
Publicado: (2023)

Observing Etna volcano dynamics through seismic and deformation patterns
por: Scarfì, L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rhcrgo5fb2p2tdc6lesrqeosia